NCT00189410

Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours

Phase II Trial With Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin (PLD) and Carboplatin in Malignant Gynecologic Tumour's

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 140 (actual)
• Sponsor: AGO Study Group · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Pegylated Liposomal Doxorubicin as well as Carboplatin have been showed efficacy in monotherapy as in combination therapy of gynaecologic tumours. As there is no common standard in the therapy of recurrent ovarian carcinoma, tumours of the uterus nor for non-epithelial ovarian tumours at time of designing of this study, this trial shall evaluate the new and well tolerated combination therapy consisting of Pegylated Liposomal Doxorubicin and Carboplatin.

Detailed description

Aim of these study is the evaluation of combination chemotherapy in a patient subset with gynecologic tumours on regard to tolerance and efficacy.

Conditions

• Cancer of the Ovary Treated as 2nd Line Therapy
• Muellerian Mixed Tumours
• Tumours of the Uterus
• Cervical Cancers
• Non-Epithelial Ovarian Tumours

Interventions

Type	Name	Description
DRUG	Pegylated Liposomal Doxorubicin and Carboplatin

Timeline

• Start date: 2003-06-01
• Primary completion: 2005-09-01
• Completion: 2006-09-01
• First posted: 2005-09-19
• Last updated: 2010-07-20

Locations

19 sites across 1 country: Germany